Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Danish (OMX) Healthcare Sector Analysis

UpdatedJan 31, 2026
DataAggregated Company Financials
Companies21
  • 7D-7.0%
  • 3M11.3%
  • 1Y-34.8%
  • YTD8.5%

Over the last 7 days, the Healthcare industry has dropped 6.0%, driven by Novo Nordisk declining 7.9%. On the other hand ViroGates is actually up 10%. However, the industry is down 34% over the past year. Looking forward, earnings are forecast to grow by 4.4% annually.

Sector Valuation and Performance

Has the Danish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 31 Jan 2026DKK 2.1tDKK 453.4bDKK 136.7b17.6x15.5x4.7x
Mon, 29 Dec 2025DKK 2.0tDKK 453.7bDKK 136.8b17.1x14.4x4.3x
Wed, 26 Nov 2025DKK 1.8tDKK 454.2bDKK 137.0b17.5x13.4x4x
Fri, 24 Oct 2025DKK 2.0tDKK 447.8bDKK 141.8b18.8x14.4x4.5x
Sun, 21 Sep 2025DKK 2.2tDKK 447.3bDKK 141.7b19x15.7x5x
Tue, 19 Aug 2025DKK 2.0tDKK 444.5bDKK 140.3b28.3x14.3x4.5x
Thu, 17 Jul 2025DKK 2.4tDKK 423.2bDKK 124.5b29.9x19.1x5.6x
Sat, 14 Jun 2025DKK 2.8tDKK 423.4bDKK 124.6b31.4x22.3x6.5x
Mon, 12 May 2025DKK 2.4tDKK 423.4bDKK 124.9b22.6x19.4x5.7x
Wed, 09 Apr 2025DKK 2.4tDKK 409.4bDKK 121.3b21.8x19.6x5.8x
Fri, 07 Mar 2025DKK 3.2tDKK 409.5bDKK 121.3b27.3x26.6x7.9x
Sun, 02 Feb 2025DKK 3.3tDKK 387.7bDKK 111.4b28.8x29.2x8.4x
Tue, 31 Dec 2024DKK 3.3tDKK 387.4bDKK 111.3b29.9x29.6x8.5x
Thu, 28 Nov 2024DKK 3.9tDKK 387.3bDKK 111.3b31.3x34.7x10x
Sat, 26 Oct 2024DKK 4.1tDKK 372.2bDKK 107.2b34x37.9x10.9x
Mon, 23 Sep 2024DKK 4.4tDKK 371.9bDKK 107.1b37.4x40.8x11.8x
Wed, 21 Aug 2024DKK 4.6tDKK 370.6bDKK 107.0b36.2x43.4x12.5x
Fri, 19 Jul 2024DKK 4.5tDKK 355.2bDKK 106.2b35.5x42.5x12.7x
Sun, 16 Jun 2024DKK 5.0tDKK 355.3bDKK 106.2b35.5x46.7x14x
Tue, 14 May 2024DKK 4.6tDKK 354.9bDKK 106.0b34.9x43.6x13x
Thu, 11 Apr 2024DKK 4.4tDKK 341.2bDKK 99.6b37.3x44.6x13x
Sat, 09 Mar 2024DKK 4.7tDKK 341.2bDKK 99.6b39.6x46.7x13.6x
Mon, 05 Feb 2024DKK 4.0tDKK 338.6bDKK 98.5b32.7x40.6x11.8x
Wed, 03 Jan 2024DKK 3.6tDKK 320.5bDKK 90.0b33x40.3x11.3x
Fri, 01 Dec 2023DKK 3.6tDKK 320.5bDKK 90.0b33.2x40.2x11.3x
Sun, 29 Oct 2023DKK 3.4tDKK 305.6bDKK 82.3b26.6x41.5x11.2x
Tue, 26 Sep 2023DKK 3.4tDKK 305.5bDKK 82.2b33.2x41x11x
Thu, 24 Aug 2023DKK 3.4tDKK 305.1bDKK 82.1b35.4x42x11.3x
Sat, 22 Jul 2023DKK 3.0tDKK 287.0bDKK 75.4b40.6x40.1x10.6x
Mon, 19 Jun 2023DKK 3.0tDKK 287.1bDKK 75.5b40.5x40.3x10.6x
Wed, 17 May 2023DKK 3.2tDKK 284.8bDKK 74.9b42x42.1x11.1x
Fri, 14 Apr 2023DKK 3.1tDKK 272.5bDKK 68.5b42.7x45x11.3x
Sun, 12 Mar 2023DKK 2.8tDKK 292.6bDKK 69.2b38.2x40.2x9.5x
Tue, 07 Feb 2023DKK 2.7tDKK 286.9bDKK 68.9b38x39.5x9.5x
Price to Earnings Ratio

39.5x


Total Market Cap: DKK 2.7tTotal Earnings: DKK 68.9bTotal Revenue: DKK 286.9bTotal Market Cap vs Earnings and Revenue0%0%0%
Danish Healthcare Sector Price to Earnings3Y Average 33.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Danish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 15.6x which is lower than its 3-year average PE of 33.4x.
  • The 3-year average PS ratio of 9.4x is higher than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 26% per year over the last three years.
  • Revenues for these companies have grown 16% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Danish Healthcare sector?

DK Market-2.76%
Healthcare-7.03%
Healthcare Services2.05%
Healthtech-0.88%
Medical Equipment-1.90%
Biotech-4.30%
Pharma-7.85%
Life Sciences-7.89%
Industry PE
  • Investors are most optimistic about the Healthcare Services industry which is trading above its 3-year average PE ratio of 297x.
    • Analysts are expecting annual earnings growth of 85.3%, which is higher than its past year's earnings decline of 99.7% per year.
Forecasted Growth
  • Analysts are most optimistic on the Healthtech industry, expecting annual earnings growth of 103% over the next 5 years.
  • In contrast, the Life Sciences industry is expected to see its earnings decline by 19% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VIRO ViroGatesDKK 12.7010.4%
+DKK 11.1m		5.0%PS14.5x
PEG Pharma Equity GroupDKK 0.114.8%
+DKK 6.1m		-30.8%PB3.4x
SMSMED Scandinavian Medical SolutionsDKK 3.982.1%
+DKK 2.2m		-32.8%PE4256.5x

Latest News

DEMANT
DKK 220.40
Demant
7D
-4.2%
1Y
-24.0%
HLUN B
DKK 42.12
H. Lundbeck
7D
-7.6%
1Y
-4.4%
ALK B
DKK 207.60
ALK-Abelló
7D
-5.4%
1Y
27.5%
SMSMED
DKK 3.98
Scandinavian Medical Solutions
7D
2.1%
1Y
-32.8%

Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)

Jan 27
Sentiment Still Eluding Scandinavian Medical Solutions A/S (CPH:SMSMED)
COLO B
DKK 536.00
Coloplast
7D
-1.1%
1Y
-35.4%

Coloplast A/S' (CPH:COLO B) P/E Is On The Mark

Jan 25
Coloplast A/S' (CPH:COLO B) P/E Is On The Mark
NOVO B
DKK 369.55
Novo Nordisk
7D
-7.9%
1Y
-39.1%

NOVO B: Wegovy Pill Launch And Execution Discipline Will Support Future Upside

Analysts have reduced their fair value estimate for Novo Nordisk to €540 from €612. They cite more moderate assumptions for revenue growth and profit margins, along with a higher discount rate and a slightly higher expected future P/E multiple.
BAVA
DKK 192.00
Bavarian Nordic
7D
-3.3%
1Y
-2.8%

BAVA: Vaccine Preparedness Contracts And Buybacks Will Support Stronger Long Term Earnings

Analysts have kept their price target for Bavarian Nordic steady at €250.00. They cite a slightly higher assumed discount rate, a smaller expected revenue decline of around 5%, a higher projected profit margin of about 17%, and a lower future P/E assumption near 23x as key inputs behind the unchanged view.
GMAB
DKK 2,022.00
Genmab
7D
-5.1%
1Y
41.9%

GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook

Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.
VIRO
DKK 12.70
ViroGates
7D
10.4%
1Y
5.0%
PEG
DKK 0.11
Pharma Equity Group
7D
4.8%
1Y
-30.8%
CHEMM
DKK 609.50
ChemoMetec
7D
-10.9%
1Y
8.8%